Endothelial and oxidative biomarker profiles in atrial fibrillation according to SGLT2 inhibitor exposure: a cross-sectional study
In a cross-sectional study of patients with non-valvular atrial fibrillation, SGLT2 inhibitor use was independently associated with elevated sVCAM-1 levels, indicating a specific effect on endothelial biomarkers without significant differences between empagliflozin and dapagliflozin or alterations in oxidative stress markers.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human heart is not just a pump; it is a complex organ lined with a delicate, living membrane called the endothelium. This inner lining acts as a gatekeeper and a communicator, releasing chemical signals that tell the rest of the body when blood vessels are under stress or when inflammation is rising. When this lining becomes irritated or activated, it releases specific proteins into the bloodstream, acting like smoke signals from a fire. One of these signals is a molecule called sVCAM-1, which helps white blood cells stick to the vessel wall, a key step in the body's inflammatory response. Another group of signals relates to oxidative stress, a process where harmful molecules damage DNA and proteins, similar to how rust weakens metal over time. Doctors have long hoped that a newer class of diabetes and heart failure drugs, known as SGLT2 inhibitors, might calm this inflammation and reduce this oxidative damage, potentially protecting the heart and blood vessels in ways beyond their known benefits.
A team of researchers in Poland set out to see if this hope was reflected in the blood of patients with atrial fibrillation, a common heart rhythm disorder. They gathered 287 adults who had been diagnosed with this condition and were taking long-term blood thinners. The group was split into two main categories: those who had been taking an SGLT2 inhibitor for at least three months and those who were not taking the drug at all. The researchers also compared the two most common types of these drugs, empagliflozin and dapagliflozin, to see if one was better than the other. They drew blood from every patient at the same time of day, before they took their morning medication, to ensure a fair comparison. The team then measured six different biological markers in the blood: three that indicated the health of the blood vessel lining and three that measured oxidative damage to DNA and proteins.
The results revealed a clear split between the two types of biological signals. The patients taking the SGLT2 inhibitors showed a distinct difference in the markers related to the blood vessel lining. Specifically, those on the medication had higher levels of the sVCAM-1 protein compared to those not taking the drug. This finding was robust; even after the researchers adjusted their analysis to account for differences in age, kidney function, diabetes, and the severity of heart failure, the higher level of this specific protein remained. In contrast, the markers for oxidative damage showed no difference at all. The levels of damaged DNA and oxidized proteins were virtually identical between the treated and untreated groups, suggesting that these drugs did not reduce this type of cellular wear and tear in the blood of these patients.
When the researchers looked closely at the two specific drugs, empagliflozin and dapagliflozin, they found them to be indistinguishable. Across all eight substances measured, there was no statistical difference between the patients taking one drug versus the other. This suggests that if there is a biological effect, it is shared by the entire class of drugs rather than being unique to one molecule. The study also clarified that the higher levels of the blood vessel marker were likely not caused by the drug itself acting as a stressor. Instead, the data pointed toward the severity of the underlying disease. Patients taking the drugs were generally sicker, with more advanced heart failure and more extensive heart damage, which is why they were prescribed the medication in the first place. The drug appeared to be a marker of a more severe condition rather than the cause of the change in the blood signal.
Ultimately, this study provides a nuanced picture of how these powerful drugs interact with the body's biology. It confirms that while SGLT2 inhibitors are associated with a specific change in the blood vessel lining, they do not appear to lower oxidative damage in the blood of patients with atrial fibrillation. The findings also indicate that doctors cannot currently choose between empagliflozin and dapagliflozin based on these specific biological markers, as the two drugs behave identically in this regard. Because the study looked at a single moment in time rather than tracking changes over months or years, it cannot prove that the drug causes these changes or that the changes are harmful. However, it does offer a clear map of where these drugs stand in the complex landscape of heart disease, showing that their biological footprint is distinct from the oxidative stress they were once hoped to erase.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.